Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WAAS
2526
DELISTED
AquaVenture Holdings Limited
WAAS
| $1.11M | ﹤0.01% |
+73,200
| New | +$1.25M |
|
|
RETA
2527
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.11M | ﹤0.01% |
35,200
+10,530
| +43% | +$259K |
|
|
RBCN
2528
DELISTED
Rubicon Technology, Inc.
RBCN
| $1.11M | ﹤0.01% |
120,240
+30,640
| +34% | +$262K |
|
2529
1-800-Flowers.com
FLWS
$262M
| $1.11M | ﹤0.01% |
113,591
+35,991
| +46% | +$366K |
|
|
ALDW
2530
DELISTED
Alon USA Partners LP
ALDW
| $1.1M | ﹤0.01% |
105,253
+51,663
| +96% | +$527K |
|
2531
Twin Disc
TWIN
$355M
| $1.1M | ﹤0.01% |
68,000
-4,000
| -6% | -$72.1K |
|
|
VSLR
2532
DELISTED
VIVINT SOLAR, INC.
VSLR
| $1.09M | ﹤0.01% |
+187,117
| New | +$640K |
|
2533
Hurco Companies Inc
HURC
$144M
| $1.09M | ﹤0.01% |
31,400
-8,281
| -21% | -$251K |
|
2534
Virtus Investment Partners
VRTS
$1.12B
| $1.09M | ﹤0.01% |
+9,829
| New | +$1.04M |
|
2535
Amtech Systems
ASYS
$280M
| $1.09M | ﹤0.01% |
129,136
+23,400
| +22% | +$171K |
|
|
SGMA
2536
DELISTED
Sigmatron International
SGMA
| $1.09M | ﹤0.01% |
169,300
+19,400
| +13% | +$116K |
|
2537
Genuine Parts
GPC
$18.7B
| $1.08M | ﹤0.01% |
+11,700
| New | +$1.08M |
|
2538
Virco
VIRC
$95.5M
| $1.07M | ﹤0.01% |
200,733
-14,867
| -7% | -$65.9K |
|
|
NSAT
2539
DELISTED
Norsat International Inc.
NSAT
| $1.07M | ﹤0.01% |
94,192
+68,192
| +262% | +$743K |
|
|
PPIH
2540
Perma-Pipe International
PPIH
$216M
| $1.07M | ﹤0.01% |
133,500
+5,800
| +5% | +$45.7K |
|
2541
Amplify Energy
AMPY
$200M
| $1.06M | ﹤0.01% |
+83,500
| New | +$1.41M |
|
|
FBMS
2542
DELISTED
The First Bancshares, Inc.
FBMS
| $1.05M | ﹤0.01% |
+38,200
| New | +$1.07M |
|
|
CIVI
2543
DELISTED
Civitas Resources
CIVI
| $1.05M | ﹤0.01% |
+33,200
| New | +$1.82M |
|
2544
Viper Energy
VNOM
$14.8B
| $1.05M | ﹤0.01% |
66,953
+51,319
| +328% | +$881K |
|
2545
Interface
TILE
$2.23B
| $1.05M | ﹤0.01% |
53,306
-117,300
| -69% | -$2.3M |
|
|
MLVF
2546
DELISTED
Malvern Bancorp, Inc.
MLVF
| $1.04M | ﹤0.01% |
43,299
+12,899
| +42% | +$287K |
|
|
APTS
2547
DELISTED
Preferred Apartment Communities, Inc.
APTS
| $1.04M | ﹤0.01% |
+65,800
| New | +$995K |
|
|
JCTC
2548
Jewett-Cameron Trading
JCTC
$10.3M
| $1.03M | ﹤0.01% |
175,000
| – | – |
|
2549
Orion Energy Systems
OESX
$78.9M
| $1.03M | ﹤0.01% |
80,500
-250
| -0.3% | -$3.71K |
|
2550
Ohio Valley Banc Corp
OVBC
$211M
| $1.02M | ﹤0.01% |
28,393
+13,493
| +91% | +$432K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.